FDA cited Signature Biologics for unapproved, unlicensed Signature Cord and serious sterile manufacturing failures.
What happened
FDA inspected Signature Biologics from December 1 to December 16, 2021, and documented manufacture of Signature Cord™, a human umbilical cord-derived product for use in other patients that was intended for injection and purported to be sterile. FDA found the product failed the minimal manipulation criterion and was marketed without an approved biologics license or an investigational new drug application. FDA also found significant deviations from current good manufacturing practice (CGMP), including aseptic process validation that did not represent the largest commercial batch, inadequate environmental monitoring, no endotoxin release testing, no process validation, no cleaning validation, and a two-year expiration date without supporting data.
What FDA found
The company marketed Signature Cord without an approved biologics license or an investigational new drug application, which FDA requires to lawfully market or study the product in humans.
42 U.S.C. 262(a); 21 U.S.C. 355(i); 21 CFR Part 312The company validated its sterile filling process with test batches smaller than its largest commercial batches.
21 CFR 211.113(b)Environmental monitoring in aseptic areas was inadequate, including no viable air monitoring with each production run and allowed high microbe counts.
21 CFR 211.42(c)(10)(iv)The company did not test each batch for endotoxin even though the product was represented as pyrogen-free.
21 CFR 211.167(a)The manufacturing process was not validated, cleaning and disinfection of biological safety cabinets and cleanrooms was not validated, and finished-product testing was limited to sterility.
21 CFR 211.100(a); 21 CFR 211.42(c)(10)(v); 21 CFR 211.160(b)The company assigned a two-year expiration date without stability data to support it.
21 CFR 211.166(a)
What FDA wants
FDA asks the company to respond in writing within 15 working days from receipt with specific steps and documentation to correct the violations and prevent recurrence. The response must also address the lack of an approved license or IND and the impact on distributed product and inventory disposition.
Who should pay attention
- health care professionals and facilities that received Signature Cord
- companies marketing human cell or tissue products
- sterile biologic manufacturers and their suppliers
This is a summary. Read the original letter on fda.gov.